Belfast’s Re-Vana in Boehringer Ingelheim deal worth up to $1bn

Contingent on milestones, Queen’s University spin-out Re-Vana Therapeutics’ strategic collaboration and license agreement with Boehringer Ingelheim is worth $1bn.

Read more: Belfast’s Re-Vana in Boehringer Ingelheim deal worth up to $1bn